170 related articles for article (PubMed ID: 36107417)
1. An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low).
Prat A; Bardia A; Curigliano G; Hammond MEH; Loibl S; Tolaney SM; Viale G
JAMA Oncol; 2022 Sep; ():. PubMed ID: 36107417
[TBL] [Abstract][Full Text] [Related]
2. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Bardia A; Viale G
Target Oncol; 2023 May; 18(3):313-319. PubMed ID: 37133651
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract][Full Text] [Related]
4. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
5. Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer.
Xu K; Bayani J; Mallon E; Pond GR; Piper T; Hasenburg A; Markopoulos CJ; Dirix L; Seynaeve CM; van de Velde CJH; Rea DW; Bartlett JMS
J Mol Diagn; 2022 Jul; 24(7):775-783. PubMed ID: 35526835
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
Peiffer DS; Zhao F; Chen N; Hahn OM; Nanda R; Olopade OI; Huo D; Howard FM
JAMA Oncol; 2023 Apr; 9(4):500-510. PubMed ID: 36821125
[TBL] [Abstract][Full Text] [Related]
7. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M; Porta FM; D'Ercole M; Pescia C; Sajjadi E; Cursano G; De Camilli E; Pala O; Mazzarol G; Venetis K; Guerini-Rocco E; Curigliano G; Viale G; Fusco N
Virchows Arch; 2024 Jan; 484(1):3-14. PubMed ID: 37770765
[TBL] [Abstract][Full Text] [Related]
8. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.
Patelli G; Zeppellini A; Spina F; Righetti E; Stabile S; Amatu A; Tosi F; Ghezzi S; Siena S; Sartore-Bianchi A
Cancer Treat Rev; 2022 Mar; 104():102351. PubMed ID: 35180563
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P
Lancet Oncol; 2019 Aug; 20(8):1124-1135. PubMed ID: 31257177
[TBL] [Abstract][Full Text] [Related]
10. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
11. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
[TBL] [Abstract][Full Text] [Related]
12. Automated Classification of Breast Cancer Across the Spectrum of
Guvakova MA
JCO Clin Cancer Inform; 2023 Jul; 7():e2300013. PubMed ID: 37437225
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G; Basik M; Niikura N; Tokunaga E; Brucker S; Penault-Llorca F; Hayashi N; Sohn J; Teixeira de Sousa R; Brufsky AM; O'Brien CS; Schmitt F; Higgins G; Varghese D; James GD; Moh A; Livingston A; de Giorgio-Miller V
ESMO Open; 2023 Aug; 8(4):101615. PubMed ID: 37562195
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.
Mouabbi JA; Singareeka Raghavendra A; Bassett RL; Hassan A; Tripathy D; Layman RM
JAMA Netw Open; 2023 May; 6(5):e2313017. PubMed ID: 37166793
[TBL] [Abstract][Full Text] [Related]
15. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt J; Rozeboom B; Dey N; De P
Am J Cancer Res; 2020; 10(4):1045-1067. PubMed ID: 32368385
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
17. The Exciting New Field of HER2-Low Breast Cancer Treatment.
Eiger D; Agostinetto E; Saúde-Conde R; de Azambuja E
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804398
[TBL] [Abstract][Full Text] [Related]
18. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review.
Tarantino P; Curigliano G; Parsons HA; Lin NU; Krop I; Mittendorf EA; Waks A; Winer EP; Tolaney SM
JAMA Oncol; 2022 Apr; 8(4):629-635. PubMed ID: 35024766
[TBL] [Abstract][Full Text] [Related]
19. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
[TBL] [Abstract][Full Text] [Related]
20. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]